Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from February 2023.
Biosimilars
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy -
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from November 2022.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from January 2022.
-
Read more: The Risk of Pervasive Trade Secret Practices Within the Life Sciences The Risk of Pervasive Trade Secret Practices Within the Life Sciences
Trade secrets offer a number of benefits for life sciences companies compared to patents, such as theoretical indefinite intellectual property protection.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of August 2021.
-
Read more: The Ongoing Step Therapy Debate The Ongoing Step Therapy Debate
Senator Lisa Murkowski’s reintroduction of the Safe Step Act has revived the debate over the prudence of step therapy protocols.
-
Read more: Pharmaceutical Patents on Manufacturing Methods: Groundless or Well-Supported? Pharmaceutical Patents on Manufacturing Methods: Groundless or Well-Supported?
Are manufacturing method patents warranted intellectual property protections, or groundless obstacles to competition?
-
Read more: When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims
In this post, I explore several problematic aspects of the court’s reasoning for rejecting the claims of pay-for-delay and market allocation.
-
Read more: Year in Review: Biosimilars Year in Review: Biosimilars
In November 2020, the FDA released its most recent draft guidance for industry on biosimilarity and interchangeability
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from October 2020.